Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.65 |
| ▸ | CASP1 | P29466 | 1/20 | 0.57 |
| ▸ | CASP4 | P49662 | 1/20 | 0.57 |
| ▸ | CASP7 | P55210 | 1/20 | 0.57 |
| ▸ | CASP9 | P55211 | 1/20 | 0.57 |
| ▸ | CASP6 | P55212 | 1/20 | 0.57 |
| ▸ | TTR | P02766 | 1/20 | 0.57 |
| ▸ | CES1 | P23141 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.54 |
| ▸ | PDE5A | O76074 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | RCE1 | Q9Y256 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29403414 | 1.00 | CASP3 (0.65) | CASP3CASP1CASP4CASP7CASP9 | |
| SCHEMBL10205375 | 0.88 | CA1 (0.50) | CASP3CASP1CASP4CASP7CASP9 | |
| SCHEMBL19657305 | 0.84 | TTR (0.57) | CASP3CASP1CASP4CASP7CASP9 | |
| SCHEMBL14867085 | 0.81 | ACHE (0.44) | CASP3ACHEAGTR1PDE5AALDH1A1 | |
| SCHEMBL16237987 | 0.78 | CASP3 (0.62) | CASP3CASP1CASP4CASP7CASP9 | |
| SCHEMBL3005504 | 0.78 | CASP3 (0.62) | CASP3CASP1CASP4CASP7CASP9 | |
| SCHEMBL31419918 | 0.78 | CASP3 (0.62) | CASP3CASP1CASP4CASP7CASP9 | |
| SCHEMBL8296661 | 0.78 | CASP3 (0.62) | CASP3CASP1CASP4CASP7CASP9 | |
| SCHEMBL5118034 | 0.78 | CASP3 (1.00) | CASP3CASP1CASP4CASP7CASP9 | |
| SCHEMBL30704879 | 0.78 | CASP3 (0.62) | CASP3CASP1CASP4CASP7CASP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109384769-B | Synthetic method of R-configuration 3-substituted-3-hydroxy oxindole compound | 陕西师范大学 | 2020-12-22 | — | — | CN | claimed |
| CN-109384769-A | A kind of synthetic method of R configuration 3- substitution -3- hydroxyl oxidized indole compounds | 陕西师范大学 | 2019-02-26 | — | — | CN | claimed |
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230365537-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| EP-3573960-B1 | N-{[2-(PIPERIDIN-1-YL)PHENYL](PHENYL)METHYL}-2-(3-OXO-3,4-DIHYDRO-2H-1,4-BENZOXAZIN-7-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ROR-GAMMA MODULATORS FOR TREATING AUTOIMMUNE DISEASES | GENFIT (FR) | 2023-08-16 | — | — | EP | disclosed |
| EP-3626699-B1 | SSAO INHIBITOR | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2023-07-12 | — | — | EP | disclosed |
| CN-109456249-B | Synthetic method of isatin derivative | 西北师范大学 | 2022-03-08 | — | — | CN | disclosed |
| EP-3288933-B1 | OXINDOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | MUSC FOUND FOR RES DEV (US) | 2021-10-06 | — | — | EP | disclosed |
| US-20210198220-A1 | SSAO INHIBITOR | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-07-01 | — | — | US | disclosed |
| US-11001563-B2 | SSAO inhibitor | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-05-11 | — | — | US | disclosed |
| CN-109384769-B | Synthetic method of R-configuration 3-substituted-3-hydroxy oxindole compound | 陕西师范大学 | 2020-12-22 | — | — | CN | disclosed |
| US-20090181960-A1 | Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer | ASTELLAS PHARMA INC. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090181960-A1 | Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer | ASTELLAS PHARMA INC. (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1990335-A1 | 17 BETA HSD TYPE 5 INHIBITOR | Astellas Pharma Inc. (JP) | 2008-11-12 | — | — | EP | disclosed |
| EP-0462831-B1 | Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase | ZENECA LTD (GB) | 1996-02-28 | — | — | EP | disclosed |
| US-5462953-A | Benzoxazolyl derivatives useful as 5-lipoxygenase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-10-31 | — | — | US | disclosed |
| US-5364877-A | Antiinflammatory agents, antiallergens | ICI PHARMA (GB) | 1994-11-15 | — | — | US | disclosed |
| US-5278177-A | Enzyme inhibitory | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-01-11 | — | — | US | disclosed |
| US-5179115-A | Antiinflammatory agents, antiallergens | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-01-12 | — | — | US | disclosed |
| EP-0462831-A2 | Bicyclic pyran derivatives and their use as inhibitors of 5-lipoxygenase | ZENECA LIMITED (GB) | 1991-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001563-B2 | SSAO inhibitor | SSB, ASAH2, AOX1 | CASP3 4111/4885CASP1 2888/4885CASP4 3238/4885 |
| US-20210198220-A1 | SSAO INHIBITOR | SSB, ASAH2, AOX1 | CASP3 4111/4885CASP1 2888/4885CASP4 3238/4885 |
| US-11858915-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | CASP3 2487/4885CASP1 3608/4885CASP4 953/4885 |
| US-20230365537-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | CASP3 2487/4885CASP1 3608/4885CASP4 953/4885 |
| US-20090181960-A1 | Selective enzyme inhibitors of 17-beta-hydroxysteroid dehydrogenase (17 beta HSD); 1-[(4-bromophenyl)sulfonyl]-1H-indole-3-carboxylic acid, andanalogues; benign prostate hyperplasia; prostate cancer; acne, seborrhea, hirsutism, baldness, alopecia, precocious puberty, adrenal hypertrophy, breast cancer | CYP17A1, HSD17B3, HSD17B1 | CASP3 1070/4885CASP1 1615/4885CASP4 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.